Antares Pharma to Host Third Quarter 2014 Operating and Financial Results Conference Call

EWING, N.J.--(BUSINESS WIRE)--

Antares Pharma, Inc. ATRS today announced it will release its third quarter 2014 financial results before the market opens on Thursday, November 6, 2014 and host a conference call at 8:30 a.m. ET (Eastern Time) to discuss the results. Eamonn P. Hobbs, President and Chief Executive Officer, and Robert F. Apple, Executive Vice President, Chief Operating Officer, will host the call.

Interested parties may participate in the conference call by dialing 1-888-576-4387 (U.S.) or 1-719-325-2432 (international) 5 to 10 minutes prior to the start of the call. The conference access code is 8566591. A replay of the conference call will be available from 11:30 a.m. ET on Thursday, November 6, 2014 through 11:30 a.m. ET on November 21, 2014 by dialing 1-888-203-1112 (U.S.) or 1-719-457-0820 (international), and entering the access code 8566591. An audio web cast and archive of the conference call will also be available under the investor relations section of the Antares Web site at www.antarespharma.com.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company markets OTREXUP™ (methotrexate) injection for subcutaneous use in the treatment of adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. LEO Pharma markets OTREXUP™ to dermatologists for adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot^® Testosterone for testosterone replacement therapy. The Company's technology platforms include VIBEX^® disposable Medi-Jet, disposable multi-use pen injectors and reusable needle-free injectors marketed as Tjet^® and Zomajet^® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin^® [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX^® epinephrine and several other products. In the U.S. Antares has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin^® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma.